Beam Therapeutics Inc. (BEAM) Cash Flow Statement
Beam Therapeutics Inc. (BEAM) generated -$359.4M of operating cash flow over the twelve months to 2026-06-30, spent $13.4M on capital expenditure and had free cash flow of -$372.8M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
BEAMBeam Therapeutics Inc.Follow BEAM — free
—
Price chart with a free account
- Market cap
- 2.5B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
| Line | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -0.10 | -0.07 | 0.02 | -0.15 | -0.35 | -0.35 | -0.36 | |
| Capital expenditure | 0.02 | 0.05 | 0.05 | 0.03 | 0.01 | 0.01 | -0.01 | |
| Free cash flow | -0.11 | -0.11 | -0.03 | -0.18 | -0.36 | -0.36 | -0.37 | |
| Stock-based compensation | 0.02 | 0.04 | 0.08 | 0.10 | 0.12 | 0.09 | — |
USD billions · SEC XBRL
Beam Therapeutics Inc. — questions
- What is Beam Therapeutics Inc.'s operating cash flow?
- -$359.4M over the twelve months to 2026-06-30.
- How much does Beam Therapeutics Inc. spend on capital expenditure?
- $13.4M over the twelve months to 2026-06-30.
- What is Beam Therapeutics Inc.'s free cash flow?
- -$372.8M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Beam Therapeutics Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.